182871-52-9

Upstream product

• 111-25-1 1-bromo-hexane 
• 182871-40-5 (2R,3S,4S,5R,6R)-3,5-Bis-benzyloxy-2-benzyloxymethyl-6-[(2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-(2-trimethylsilanyl-ethoxy)-tetrahydro-pyran-2-ylmethoxy]-tetrahydro-pyran-4-ol 
• 182872-36-2 Trimethyl-[2-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-{(2R,3R,4S,5R,6R)-3,5-bis-benzyloxy-6-benzyloxymethyl-4-[((E)-propenyl)oxy]-tetrahydro-pyran-2-yloxymethyl}-tetrahydro-pyran-2-yloxy)-ethyl]-silane 
• 182871-36-9 {2-[(2R,3R,4S,5R,6R)-6-((2R,3R,4S,5R,6R)-4-Allyloxy-3,5-bis-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yloxymethyl)-3,4,5-tris-benzyloxy-tetrahydro-pyran-2-yloxy]-ethyl}-trimethyl-silane 
• 100-39-0 benzyl bromide 

Relevant academic research and scientific papers

Design and synthesis of gentiohexaosyl derivatives for an ANP receptor antagonist, HS-142-1

A hexaosyl fragment of the major component of lipooligosaccharide HS- 142-1, O-(3-O-caproyl-β-D-glucopyranosyl)-(1→6)-[O-(β-D-glucopyranosy l)- (1→6)-O-(3-O-caproyl-β-D-glucopyranosyl)-(1→ 6)]2-D-glucopyranose (1), was efficiently synthesized by block synthesis. More stable analogs, O-(3-O- hexyl-B-D-glucopyranosyl)-(1→6)-[O-(B-D-glucopyranosyl)-(1→6)-O -(3-O-hexyl- β-D-glucopyranosyl)-(l→6)]2-D-glucopyranose (4) and O-(3-O-caproyl-2,4,6- tri-O-methyl-β-D-glacopyranosyl)-(1→6)-[O(2,3,4-tri-O-methyl-β -D- glucopyranosyl)-(1→6)-O-(3-O-caproyl-2,4-di-O-methyl-β-D-glucop yranosyl)- (1→6)]2-2,3,4-tri-O-methyl-D-glucopyranose (2), were also designed and synthesized in a similar manner.